

INFORMATION DISCLOSURE CITATION

PTO-1449

ATTORNEY'S DKT NO.
23522.0643APPLICATION NO.
09/436,347APPLICANT
Christine A. White et al.FILING DATE
November 9, 1999GROUP
1642

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

amb	Byrd, J.C. et al., "Rituximab Therapy in Hematologic Malignancy Patients with Circulating Blood Tumor Cells; Association with Increased Infusion-Related Side Effects and Rapid Tumor Lysis" <u>Blood</u> , Vol. 92 (10, Supp. 1):106A (1998) p. 433.
amb	Byrd, J.C. et al., "Rituximab Therapy in Hematologic Malignancy Patients with Circulating Blood Tumor Cells; Association with Increased Infusion-Related Side Effects and Rapid Blood Tumor Clearance" <u>Journal of Clinical Oncology</u> , Vol. 17, No. 3 (March 1999) pp. 791-795.
amb	Berinstein, N.L. et al., "Association of Serum Rituximab (IDEC-C2B8) Concentration and Anti-Tumor Response in the Treatment of Recurrent Low-Grade or Follicular Non-Hodgkin's Lymphoma" <u>Annals of Oncology</u> , Vol. 9 (1998) pp. 995-1001.
amb	Byrd, John C., "Rituximab Therapy in Patients with Chronic Lymphocytic Leukemia" <u>Biotherapy and Radio Pharm</u> , Vol. 14, No. 4 (1999) p. 323.
↓	O'Brien, S., "Phase I/II Study of Rituxan in Chronic Lymphocytic Leukemia (CLL)" <u>Blood</u> , Vol. 92 (10, Supp.1): 105a (1998) p. 431. <i>Abstract only.</i>
↓	Maloney, David G. et al., "IDEC-C2B8: Results of a Phase I Multiple-Dose Trial in Patients with Relapsed Non-Hodgkin's Lymphoma" <u>Journal of Clinical Oncology</u> , Vol. 15, No. 10 (October 1997) pp. 3266-3274.
amb	Robinson, Randy et al., "Chimeric Mouse-Human Anti-Carcinoma Antibodies that Mediate Different Anti-Tumor Cell Biological Activities" <u>Hum. Antibod. Hybridomas</u> , Vol. 2 (April 1991) pp. 84-93.
amb	Reff, Mitchell et al., "Depletion of B Cells In Vivo by a Chimeric Mouse Human Monoclonal Antibody to CD20" <u>Blood</u> , Vol. 83, No. 2 (January 15, 1994) pp. 435-445.
amb	Liu, Alvin Y. et al., "Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 with Potent Fc-Dependent Biologic Activity" <u>Journal of Immunology</u> , Vol. 139, No. 10 (November 15, 1987) pp. 3521-3526.
↓	DeNardo, Sally J. et al., "The Biologic Window for Chimeric L6 Radioimmunotherapy" <u>Cancer Supplement</u> , Vol. 73, No. 3 (February 1, 1994) pp. 1023-1032.
↓	Attachment from The Second Annual IBC International Conference on Antibody Engineering (December 16-18, 1991) San Diego, CA <i>Abstract only</i>

EXAMINER

amb Harris

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.